Publications
Publications
Show Results For
-
All HBS Web
(14,784)
- Faculty Publications (143)
Page 1 of
143
Results
→
- Spring 2021
- Article
Ten Year Sunset Rule for Healthcare Regulation Is a Nonstarter and Discouragement to Post-COVID-19 Investment
By: Regina E. Herzlinger and Eugene Schneller
U.S. healthcare delivery has not benefitted from the same productivity growth as many other service industries, such as bricks and mortar retailing, a loss that has gravely diminished cost control and access. Regulatory capture, which creates barriers to venture...
View Details
- March, 2021
- Article
Ushering in Safe, Effective, Secure, and Ethical Medicine in the Digital Era
By: William J. Gordon, Andrea Coravos and Ariel Dora Stern
From clinical trials to care delivery, advanced, digitally enabled technologies and analytics offer new approaches to how we think about medicine, health, and biology. The COVID-19 pandemic has accelerated this conversation, and forced a roadmap, once measured in years...
View Details
- February 2021 (Revised April 2021)
- Case
Marvin: A Personalized Telehealth Approach to Mental Health
By: Regina E. Herzlinger, Thomas Arsenault, Julia Kelley, Carin-Isabel Knoop, Andrew Nguyen and Eshani Sharma
More than one third of Americans were said to suffer some type of behavioral health ailment at some point in their lifetime, with many people requiring chronic therapy or intervention. Despite significant clinical needs, access to reliable treatment has been difficult...
View Details
- January 2021
- Case
Digital Transformation 2.0: CEO Elie Girard at Atos
By: Tsedal Neeley and James Barnett
Elie Girard has taken the helm as CEO of Atos—multinational IT giant—to lead the company into the next era of digital transformation. Noticing that customers’ digital needs were evolving to become even more specialized and global in scope, he made a bold first step as...
View Details
- Article
Want to See the Future of Digital Health Tools? Look to Germany
By: Ariel Dora Stern, Henrik Matthies, Julia Hagen, Jan B. Brönneke and Jörg F. Debatin
A new law will make it easier to introduce and determine the benefits of new tools. Perhaps its most important provisions are its formalization of “prescribable applications,” which include standard software, SaaS, and mobile as well as browser-based apps, and the...
View Details
- 1 Dec 2020
- Interview
Digital Health Care: Empowering Consumers
Regina Herzlinger, the Nancy R. McPherson Professor of Business Administration, has been studying the health care sector for nearly half a century. In that time, she has seen significant innovation in the field—and she has also seen the powerful sway of the status quo,...
View Details
- October 8, 2020
- Article
What Values and Priorities Mean for Health Reform
By: Katherine Baicker and Amitabh Chandra
- October 2020
- Supplement
OpenIDEO (B)
By: Karim R. Lakhani, Anne-Laure Fayard, Manos Gkeredakis and Jin Hyun Paik
In the midst of 2020, as the coronavirus pandemic was unfolding, OpenIDEO—an online open innovation platform focused on design-driven solutions to social issues—rapidly launched a new challenge to improve access to health information, empower communities to stay safe...
View Details
Keywords:
Innovation Competitions;
Ideo;
Contests;
Contest Design;
Platforms And Ecosystems;
Open Innovation;
Open And User Innovation Strategy;
Diversity;
Design;
Social Entrepreneurship;
Global Range;
Collaborative Innovation And Invention;
Innovation Strategy;
Organizational Change And Adaptation;
Social And Collaborative Networks;
health Pandemics;
health;
Information;
Business And Community Relations
- 2020
- Working Paper
Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works; 2) the foundational advances and discoveries; 3)...
View Details
- September 2020
- Article
Regulatory Sandboxes: A Cure for mHealth Pilotitis?
By: Abhishek Bhatia, Rahul Matthan, Tarun Khanna and Satchit Balsari
Mobile health (mHealth) and related digital health interventions in the past decade have not always scaled globally as anticipated earlier despite large investments by governments and philanthropic foundations. The implementation of digital health tools has suffered...
View Details
- Article
Do We Spend Too Much on Health Care?
By: Katherine Baicker and Amitabh Chandra
Health system reforms—such as changes in insurance design, patient cost sharing, payment reform, or price regulation—should be judged by whether they move us toward higher-value use of resources, rather than by whether they reduce spending.
View Details
- Article
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study
By: Noy Alon, Ariel Dora Stern and John Torous
BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous...
View Details
- Article
Germany's Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries
By: Sara Gerke, Ariel D. Stern and Timo Minssen
Reimbursement is a key challenge for many new digital health solutions, whose importance and value have been highlighted and expanded by the current COVID-19 pandemic. Germany’s new Digital Healthcare Act (Digitale–Versorgung–Gesetz or DVG) entitles all individuals...
View Details
- July 2020
- Article
Lessons From The Impact of Price Regulation on The Pricing Of Anticancer Drugs in Germany
By: Victoria D. Lauenroth, Aaron S. Kesselheim, Ameet Sarpatwari and Ariel Dora Stern
Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the U.S., it remains largely unaddressed there. In Europe, however, different approaches to regulating drug prices have been...
View Details
- 2020
- Working Paper
SSRIs and Non-SSRIs: Case Histories of Significant Medical Advances
By: Amar Bhidé, Srikant M. Datar and Katherine Stebbins
Prozac is widely hailed as “a breakthrough drug for depression.” In 2020, the World Health Organization (WHO) estimated that over 264 million people worldwide suffer from depression, and 800,000 die by suicide each year. In 2014, researchers calculated the economic...
View Details
- 2020
- Working Paper
Tamoxifen: Case Histories of Significant Medical Advances
By: Amar Bhidé, Srikant Datar and Katherine Stebbins
Our case history describes the development of tamoxifen, considered a “gold standard” treatment for millions of breast cancer patients. Specifically, we describe breast cancer treatments prior to tamoxifen’s development; the initial development of tamoxifen from 1960...
View Details
- 2020
- Working Paper
Cephalosporins: Case Histories of Significant Medical Advances
By: Amar Bhidé, Srikant Datar and Katherine Stebbins
Our case history describes the development of three generations of cephalosporins – antibiotics that have significantly reduced hospital infections. Specifically, we chronicle how: 1) Early (pre-cephalosporin) antibiotics were developed in the first half of the 20th...
View Details
- June 2020 (Revised February 2021)
- Supplement
Accounting for Leases at American Airlines (B)
By: Jonas Heese, Gerardo Pérez Cavazos and Julia Kelley
This is a supplement to the “Accounting for Leases at American Airlines (A)” case. The (B) case describes American Airlines’ financial results for the first quarter of 2020, as well as the continuing effects of coronavirus on the airline industry.
View Details
Keywords:
Accounting;
Financial Reporting;
Financial Statements;
Finance;
Governance;
Corporate Accountability;
Corporate Governance;
Governing Rules, Regulations, And reforms;
Governing And Advisory Boards;
Leasing;
health Pandemics;
Accounting Industry;
Air Transportation Industry;
North And Central America;
United States
- 2020
- Working Paper
How Should U.S. Bank Regulators Respond to the COVID-19 Crisis?
Drawing on lessons from the 2007–2009 Global Financial Crisis (GFC) and a simple conceptual framework, we examine the response of U.S. bank regulators to the COVID-19 pandemic. We argue that the current regulatory strategy of “watchful waiting”—the same strategy that...
View Details
- June 2020
- Article
How Scheduling Can Bias Quality Assessment: Evidence from Food Safety Inspections
By: Maria Ibanez and Michael W. Toffel
Accuracy and consistency are critical for inspections to be an effective, fair, and useful tool for assessing risks, quality, and suppliers—and for making decisions based on those assessments. We examine how inspector schedules could introduce bias that erodes...
View Details